MacroGenics to Participate in Upcoming Investor Conferences
Rhea-AI Summary
MacroGenics, Inc. (Nasdaq: MGNX) will participate in upcoming investor conferences, including The Citizens JMP Life Sciences Conference and TD Cowen’s 5th Annual Oncology Innovation Summit. President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will be involved in fireside chats and one-on-one meetings, with webcasts available on the company's website.
Positive
- None.
Negative
- None.
News Market Reaction – MGNX
In the trading session that priced this news, MGNX gained 32.33%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ROCKVILLE, MD, May 13, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences this month:
-
- The Citizens JMP Life Sciences Conference (New York). MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in a fireside chat on Tuesday, May 14, 2024, at 10:30 am ET. MacroGenics’ management will also participate in one-on-one meetings.
- TD Cowen’s 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA (Virtual). MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in a fireside chat on Wednesday, May 29, 2024, at 12:30 pm ET.
Webcasts of the above presentations may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm. The Company will maintain archived replays of these webcasts on its website for 30 days.
About MacroGenics, Inc.
MacroGenics (the Company) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.
###
